| Document Date: 2013-06-20 09:22:52
Open Document File Size: 2,05 MBShare Result on Facebook
City Philadelphia / New York / Rehovot / / Company R Aharonov 2 1Rosetta Genomics Inc. / 2Rosetta Genomics Ltd / / Country Israel / United States / / Currency pence / / Facility NYU Langone Medical Center / / IndustryTerm printing / diagnostic products / / MedicalCondition especially primary lung adenocarcinoma / cancers / epithelial tumors / aggressive neoplasm / Mesothelioma / Mesothelioma Mesothelioma / Malignant Pleural Mesothelioma / malignant mesothelioma / tumors / lung adenocarcinomas / Malignant Pleural Mesothelioma M Sanden1 / Transitional Cell Carcinoma / Renal Cell Carcinoma / pleural mesothelioma / carcinomas / / MedicalTreatment Thoracic Surgery / / Organization NYU Langone Medical Center / / Person Rosetta Genomics / / Position pathologist / / Product LG 200C Cellular Phone / / ProvinceOrState New York / Pennsylvania / / Technology microRNA based diagnostic products / microRNA based diagnostic / /
SocialTag |
Further Validation of a microRNA-Based Diagnostic Assay for Malignant Pleural Mesothelioma M Sanden1, H Benjamin2, K Ashkenazi1, Y Spector2, H Mitchell1, E Meiri2, D Lebanony2, H Pass3 and R Aharonov 2 1Rosetta Genomics